首页> 外文OA文献 >Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models

【2h】

Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models

机译：选择性雌激素受体降解剂（SERD），具有抗肿瘤活性，在多er +乳腺癌患者衍生的异种移植模型中具有抗肿瘤活性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Teeru Bihani; Hitisha K. Patel; Heike Arlt; Nianjun Tao; Hai Jiang; Jeffrey L. Brown; Dinesh M. Purandare; Gary Hattersley; Fiona Garner;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models [J] . Bihani Teeru, Patel Hitisha K., Arlt Heike, Clinical cancer research: an official journal of the American Association for Cancer Research . 2017,第16期

机译：选择性雌激素受体降解剂（SERD），具有抗肿瘤活性，在多er +乳腺癌患者衍生的异种移植模型中具有抗肿瘤活性
2. EMERALD: A randomized, open-label, phase 3 trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine therapy for ER+/HER2-advanced breast cancer following CDK4/6 inhibitor therapy [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：祖母绿：一个随机的，开放标签，第3阶段试验，以评估享受新的口服选择性雌激素受体降解剂（SERD），VS调查患者对ER + / HER2晚期乳腺癌的内分泌治疗选择的疗效和安全性 CDK4 / 6抑制剂治疗
3. Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：最终分析阶段1对雌激素（RAD1901）的研究，一种新颖的选择性雌激素受体降解剂（SERD），雌激素受体阳性（ER加），人表皮生长因子受体2阴性（HER2-）晚期乳腺癌
4. Higher isobaric multiplexing for discovery proteomics of genomically-characterized patient-derived breast cancer xenografts [C] . Xuya Wang, Petra Erdmann-Gilmore, Alan E. Davis, ASMS Conference on Mass Spectrometry and Allied Topics . 2015

机译：基因组特征患者衍生的乳腺癌异种移植物的发现蛋白质组学更高的同学复用
5. Estrogen receptor, growth factor receptor and protooncogene protein activities and possible signal transduction crosstalk in estrogen dependent and independent breast cancer cell lines [D] . Mohamood, Abdiaziz Sheikh 1995

机译：雌激素依赖性和非依赖性乳腺癌细胞系中的雌激素受体，生长因子受体和原癌基因蛋白活性以及可能的信号转导串扰
6. RAD1901: a novel orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models [O] . Fiona Garner, Maysoun Shomali, Dotty Paquin, -1

机译：RAD1901：一种新型的可口服生物利用的选择性雌激素受体降解剂在乳腺癌异种移植模型中显示出抗肿瘤活性
7. Basic selective estrogen receptor degraders (B-SERDs) in combination with novel BET inhibitors in ER+ breast cancer [O] . R. Xiong, Y. Li, J. Zhao, 2019

机译：基本选择性雌激素受体降解剂（B-SERDS）与ER +乳腺癌的新型BET抑制剂组合

Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models

著录项

引文网络

相似文献

相关主题

期刊订阅